## Filomena De Nigris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3507232/publications.pdf

Version: 2024-02-01

63 4,280 38 62 g-index

63 63 63 63 5503

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. Cancers, 2022, 14, 3414.	3.7	7
2	Clinical efficiency of epigenetic drugs therapy in bone malignancies. Bone, 2021, 143, 115605.	2.9	28
3	Epigenetic therapies of osteoporosis. Bone, 2021, 142, 115680.	2.9	11
4	Lysosome purinergic receptor P2X4 regulates neoangiogenesis induced by microvesicles from sarcoma patients. Cell Death and Disease, 2021, 12, 797.	6.3	14
5	Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. Frontiers in Endocrinology, 2020, 11, 604341.	3.5	27
6	Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer. Molecular Therapy - Nucleic Acids, 2019, 17, 256-263.	5.1	25
7	Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. British Journal of Cancer, 2019, 121, 979-982.	6.4	68
8	Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study. Cancers, 2019, 11, 1444.	3.7	25
9	New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions. Expert Review of Clinical Immunology, 2019, 15, 289-301.	3.0	15
10	STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma. Molecular Therapy - Nucleic Acids, 2018, 10, 398-411.	5.1	72
11	Epigenetic Hallmarks of Fetal Early Atherosclerotic Lesions in Humans. JAMA Cardiology, 2018, 3, 1184.	6.1	58
12	Sarcoma Spheroids and Organoidsâ€"Promising Tools in the Era of Personalized Medicine. International Journal of Molecular Sciences, 2018, 19, 615.	4.1	57
13	The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 449-455.	7.4	37
14	Post-surgery fluids promote transition of cancer stem cell-to-endothelial and AKT/mTOR activity, contributing to relapse of giant cell tumors of bone. Oncotarget, 2017, 8, 85040-85053.	1.8	12
15	New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder Cancer. Genes, 2016, 7, 127.	2.4	26
16	Epigenetic regulators: Polycomb-miRNA circuits in cancer. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 697-704.	1.9	16
17	Polycomb YY1 is a critical interface between epigenetic code and miRNA machinery after exposure to hypoxia in malignancy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 975-986.	4.1	19
18	Endothelial Cell Tube Formation on Basement Membrane to Study Cancer Neoangiogenesis., 2015,, 13-22.		1

#	Article	IF	CITATIONS
19	Involvement of Mediator complex in malignancy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 66-83.	7.4	67
20	Osteosarcoma cells induce endothelial cell proliferation during neoâ€angiogenesis. Journal of Cellular Physiology, 2013, 228, 846-852.	4.1	28
21	Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells. Cancers, 2013, 5, 404-417.	3.7	4
22	CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 251-264.	1.6	53
23	Glycoxydation promotes vascular damage Via MAPKâ€ERK/JNK pathways. Journal of Cellular Physiology, 2012, 227, 3639-3647.	4.1	7
24	YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma. BMC Cancer, 2011, 11, 472.	2.6	42
25	Directed <i>in vivo</i> angiogenesis assay and the study of systemic neoangiogenesis in cancer. International Journal of Cancer, 2011, 128, 1505-1508.	5.1	23
26	CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14484-14489.	7.1	104
27	Therapeutic angiogenesis in diabetic apolipoprotein E-deficient mice using bone marrow cells, functional hemangioblasts and metabolic intervention. Atherosclerosis, 2010, 209, 403-414.	0.8	18
28	p66ShcDeletion Confers Vascular Protection in Advanced Atherosclerosis in Hypercholesterolemic Apolipoprotein E Knockout Mice. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 276-287.	1.7	49
29	Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. American Heart Journal, 2008, 156, 1154.e1-1154.e8.	2.7	47
30	Therapeutic dose of nebivolol, a nitric oxide-releasing $\hat{l}^2$ -blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric Oxide - Biology and Chemistry, 2008, 19, 57-63.	2.7	34
31	Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. European Journal of Cancer, 2008, 44, 334-340.	2.8	57
32	Deletion of Yin Yang 1 Protein in Osteosarcoma Cells on Cell Invasion and CXCR4/Angiogenesis and Metastasis. Cancer Research, 2008, 68, 1797-1808.	0.9	77
33	Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 571-579.	3.3	33
34	Evidence of Key Role of Cdk2 Overexpression in Pemphigus Vulgaris. Journal of Biological Chemistry, 2008, 283, 8736-8745.	3.4	44
35	Effects of a Pomegranate Fruit Extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis. Cardiovascular Research, 2007, 73, 414-423.	3.8	78
36	Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3597-3602.	7.1	79

#	Article	IF	CITATIONS
37	The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. Nitric Oxide - Biology and Chemistry, 2007, 17, 50-54.	2.7	119
38	Therapeutic effects of concurrent autologous bone marrow cell infusion and metabolic intervention in ischemia-induced angiogenesis in the hypercholesterolemic mouse hindlimb. International Journal of Cardiology, 2007, 117, 238-243.	1.7	16
39	Expression of transcription factor Yin Yang 1 in human osteosarcomas. European Journal of Cancer, 2006, 42, 2420-2424.	2.8	61
40	Pomegranate juice reduces oxidized low-density lipoprotein downregulation of endothelial nitric oxide synthase in human coronary endothelial cells. Nitric Oxide - Biology and Chemistry, 2006, 15, 259-263.	2.7	45
41	Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide. Nitric Oxide - Biology and Chemistry, 2006, 15, 93-102.	2.7	137
42	Nitric oxide and atherosclerosis: An update. Nitric Oxide - Biology and Chemistry, 2006, 15, 265-279.	2.7	391
43	Glycoxidation of low–density lipoprotein promotes multiple apoptotic pathways and NFkB activation in human coronary cells. Basic Research in Cardiology, 2006, 101, 101-108.	5.9	11
44	Rethinking Primary Prevention of Atherosclerosis-Related Diseases. Circulation, 2006, 114, 2517-2527.	1.6	88
45	Physical training and metabolic supplementation reduce spontaneous atherosclerotic plaque rupture and prolong survival in hypercholesterolemic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10479-10484.	7.1	50
46	Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimb. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17202-17206.	7.1	69
47	Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4896-4901.	7.1	126
48	Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8797-8802.	7.1	106
49	Glycoxidation of Low-Density Lipoprotein Increases TUNEL Positivity and CPP32 Activation in Human Coronary Cells. Annals of the New York Academy of Sciences, 2003, 1010, 710-715.	3.8	4
50	Deletion of the p66 <sup>Shc</sup> longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2112-2116.	7.1	362
51	Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. Trends in Molecular Medicine, 2003, 9, 351-359.	6.7	96
52	Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1420-1425.	7.1	98
53	Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12467-12470.	7.1	67
54	Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1689-1694.	7.1	77

#	ARTICLE	IF	CITATIONS
55	Maternal Hypercholesterolemia During Pregnancy Promotes Early Atherogenesis in LDL Receptor-Deficient Mice and Alters Aortic Gene Expression Determined by Microarray. Circulation, 2002, 105, 1360-1367.	1.6	145
56	Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells. Journal of the American College of Cardiology, 2002, 40, 1515-1522.	2.8	41
57	New insights in the transcriptional activity and coregulator molecules in the arterial wall. International Journal of Cardiology, 2002, 86, 153-168.	1.7	29
58	Multiple role of reactive oxygen species in the arterial wall. Journal of Cellular Biochemistry, 2001, 82, 674-682.	2.6	216
59	Modulation by $\hat{l}_{\pm}$ - and $\hat{l}_{\pm}$ -tocopherol and oxidized low-density lipoprotein of apoptotic signaling in human coronary smooth muscle cellsa $\hat{l}_{\pm}$ —. Biochemical Pharmacology, 2000, 59, 1477-1487.	4.4	61
60	Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB Journal, 2000, 14, 1996-2007.	0.5	191
61	Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits. General Pharmacology, 1999, 33, 467-477.	0.7	42
62	Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosome. Nature Genetics, 1995, 10, 13-19.	21.4	190
63	Analysis of the OA1 gene reveals mutations in only one-third of patients with X-linked ocular albinism. Human Molecular Genetics, 1995, 4, 2319-2325.	2.9	80